Minnesota AG Negotiates Insulin Price Cap with Eli Lilly

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • Minnesota AG Keith Ellison settled with Eli Lilly and Co. to resolve allegations the pharmaceutical company deceptively priced its insulin products, causing certain patients to pay higher “list” prices for the drugs than others.
  • The lawsuit alleged that Eli Lilly fraudulently set an artificially high list price for its insulin products while negotiating a lower actual price with pharmacy benefit managers for individuals with insurance, resulting in underinsured and uninsured patients paying the higher list price.
  • Under the terms of the settlement, Eli Lilly will cap the out-of-pocket cost of monthly prescriptions for consumers in the state at $35 for the next five years, and provide free insulin products to state non-profit clinics for five years.
  • As we recently covered, New York AG Letitia James negotiated similar insulin price caps with Eli Lilly, Sanofi-Aventis U.S. LLC, and Novo Nordisk Inc.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide